Arriello

Global and local #regulatoryaffairs, #pharmacovigilance, #medicalwriting & #translation experts. From development to market. Faster, Better and Smarter.

[Arriello @arriello_group]

Global PV expert and @arriello_group board advisor, John Price takes a look at our recent survey data into PV automation here in @PharmExec https://t.co/Hl6bUrXKXw #lifesciences #pharmacovigilance #outsourcingservices #AI

[Arriello @arriello_group]

World Drug Safety Congress Americas in Boston this Oct will bring together 600+ top leaders in biopharma to discuss the key challenges they are facing in pharmacovigilance and device safety https://t.co/dpCtE5PIet @WDS_event #WDS #pharmacovigilance #lifesciences #biotechnology

[Arriello @arriello_group]

The World Drug Safety Congress Americas 2021 is happening in Boston this Oct 20-21 and we’ll be there https://t.co/dpCtE5PIet @WDS_event #WDS #pharmacovigilance #automation #lifesciences #biotechnology

[Arriello @arriello_group]

HMA-EMA plans real-world metadata framework for regulatory decision-making https://t.co/MTLYTpmBUt @RAPSorg #EMA #pharmacovigilance #lifesciencs

[Arriello @arriello_group]

Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, September 2021 https://t.co/Wf9WVhffNk @PharmaReview #pharmacovigilance #PRAC #EMA #LifeSciences

[Arriello @arriello_group]

Accelerating the future of Remote Auditing offers advice, insights, and top tips and you can get your copy here https://t.co/3wjn0hRerr #pharmacovigilance #audits #lifesciences #pharmaceuticals #future #healthcare #compliance

[Arriello @arriello_group]

Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, July 2021 @PharmaReview https://t.co/UROX0hJSHE #pharmacovigilance #regulatoryreporting #PRAC #EMA

[Arriello @arriello_group]

Pharmacovigilance Risk Assessment Committee meeting highlights, June 2021 @PharmaReview https://t.co/zD2I3X6OK2 #Pharmacovigilance #EMA #PRAC

[Arriello @arriello_group]

EMA updates COVID-19 vaccine risk management plans to reflect variant safety @RAPSorg #EMA #RMP #Pharmacovigilance https://t.co/xEV6MhP4b6

[Arriello @arriello_group]

In this article in @PharmTechGroup @arriello_group board advisors Judith Sills and Eric Caugant guide us through the differing safety demands of respective regulators https://t.co/W0Qoj7uykt #pharmacovigilance #biotech

[Arriello @arriello_group]

Navigating pharmacovigilance complexity in the US and EU. Non-executive advisors to @arriello_group Eric Caugant and Judith Sills chart the main differences between US and EU requirements. https://t.co/CgSPM0gwTD @PharmaReview #pharmacovigilance #biotechnologyindustry

[Arriello @arriello_group]

Outsourcing without focusing on safety is turning out to be a costly decision for pharma companies says @arriello_group Manager Natalia Vlcek-Zasepa in this article published in @DDWJournal https://t.co/AJUwKyq0MU #clinicalresearch #safety #outsourcing #pharma

[Arriello @arriello_group]

Pharma companies outsourcing clinical research support without focusing on safety are paying the price explains @arriello_group Pharmacovigilance Manager and EU QPPV at Arriello, Natalia Vlcek-in @PharmaReview https://t.co/ZkOox2eIFh #clinicalresearch #outsourcing #safety

[Arriello @arriello_group]

New article on Navigating international divergence on pharmacovigilance: Tips for Biotechs from our @arriello board advisors, Judith Sills and Eric Caugant. Published today in @PharmExec #pharmacovigilance #biotech #pharmaceuticals #safety

[Arriello @arriello_group]

The compelling opportunity for Medical Cannabis in Europe via @PharmaTechFocus and @arriello_group 's director of Product Safety, Peter Kohut https://t.co/ZFokB82esM #medicalcannabis #lifesciences #regulations

[Arriello @arriello_group]

EMA: J&J vaccine possibly linked to rare clots; benefit outweighs risk https://t.co/R81sPKvVQA @RAPSorg #EMA #pharmacovigilance #lifesciences

[Arriello @arriello_group]

Marketing Medical Cannabis in Europe.
@arriello director of drug safety Peter Kohut gives his advice in the latest issue of International Pharmaceutical Industry https://t.co/damMDBE8bC #cannabis #lifesciences #regulatory

[Arriello @arriello_group]

Our head of clinical safety management, Alexandra Iuliana Lazar-Giannakopoulou reflects on the MHRA's updated guidelines to assist companies involved in clinical trials disrupted as a result of the Covid-19 pandemic. https://t.co/s2zjtmpcZz #clinicaltrials #pandemic #guidelines

[Arriello @arriello_group]

FDA offers guidance on generic drug development during COVID https://t.co/1vJX8H3ESL @RAPSorg #FDA #ANDA #pharmacovigilance

[Arriello @arriello_group]

FDA issues 36 new and revised product-specific guidances https://t.co/eUNfBIoz70 @RAPSorg #FDA #pharmacovigilance #lifesciences #regulatoryaffairs